Table 1 Baseline characteristics of 116 patients
From: CPA4 overexpression correlates with poor prognosis and tumor progression in endometrial cancer
Characteristic | Low expression of CPA4 | High expression of CPA4 | p |
|---|---|---|---|
n | 58 | 58 | Â |
Tumor invasion (%), n (%) | Â | Â | 0.316 |
  < 50 | 43 (37.1%) | 37 (31.9%) |  |
  >  = 50 | 15 (12.9%) | 21 (18.1%) |  |
Histological type, n (%) | Â | Â | 0.756 |
 Endometrioid | 51 (44%) | 49 (42.2%) |  |
 Mixed | 6 (5.2%) | 6 (5.2%) |  |
 Serous | 1 (0.9%) | 3 (2.6%) |  |
Histologic grade, n (%)a | Â | Â | 0.008 |
 G1 | 28 (24.8%) | 16 (14.2%) |  |
 G2 | 20 (17.7%) | 37 (32.7%) |  |
 G3 | 8 (7.1%) | 4 (3.5%) |  |
Lymphatic metastasis, n (%)a | Â | Â | 1.000 |
 No | 37 (40.2%) | 41 (44.6%) |  |
 Yes | 7 (7.6%) | 7 (7.6%) |  |
FIGO grade, n (%)b | Â | Â | 0.062 |
 Stage I | 45 (38.8%) | 36 (31%) |  |
 Stage II | 5 (4.3%) | 8 (6.9%) |  |
 Stage III | 6 (5.2%) | 14 (12.1%) |  |
 Stage IV | 2 (1.7%) | 0 (0%) |  |
Age, n (%) | Â | Â | 1.000 |
  < 55 | 27 (23.3%) | 26 (22.4%) |  |
  >  = 55 | 31 (26.7%) | 32 (27.6%) |  |
Radiation therapy, n (%) | Â | Â | 0.401 |
 No | 45 (38.8%) | 40 (34.5%) |  |
 Yes | 13 (11.2%) | 18 (15.5%) |  |
Menopause status, n (%) | Â | Â | 0.116 |
 No | 15 (12.9%) | 24 (20.7%) |  |
 Yes | 43 (37.1%) | 34 (29.3%) |  |
Diabetes, n (%) | Â | Â | 0.806 |
 No | 47 (40.5%) | 49 (42.2%) |  |
 Yes | 11 (9.5%) | 9 (7.8%) |  |
Ki67, median (IQR) | 47.5 (30, 70) | 60 (46.25, 70) | 0.031 |
AOD, median (IQR) | 0.2 (0.18, 0.21) | 0.25 (0.23, 0.27) |  < 0.001 |